Opdivo replaces Nivolumab BMS for treatment of lung cancer

Opdivo (nivolumab) is now indicated in the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy, in addition to its original indication in melanoma.

Nivolumab was originally launched for the treatment of NSCLC as Nivolumab BMS, but the manufacturer has now reconciled both indications under the Opdivo brand name. The two brands contain identical presentations of nivolumab and the same dosage regimen is used in both types of cancer.

The discontinuation of Nivolumab BMS will have no impact on patients with lung cancer already being prescribed nivolumab, other than a change in the brand name of their treatment. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...